MHRA approves TMC Pharma's fosdenopterin for MoCD type A

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved TMC Pharma’s fosdenopterin (Nulibry) for the treatment of molybdenum cofactor deficiency (MoCD) type A.

This rare genetic disorder is characterised by the body’s inability to produce cyclic pyranopterin monophosphate, leading to toxic sulphite accumulation that damages the brain. Symptoms apparent from birth include seizures, poor muscle tone and small head size.

The authorisation, which is based on a decision by the European Commission (EC) and advice from the Committee for Medicinal Products for Human Use, follows the EC decision reliance procedure.

Fosdenopterin is offered as a 9.5mg powder in solution for injection, administered intravenously through a catheter.

It has demonstrated benefits in five main studies enrolling 52 subjects with MoCD type A. These trials assessed the impact of fosdenopterin on survival following a treatment period of one year.

93% of subjects treated with fosdenopterin survived beyond one year, in contrast to a 75% survival rate in those who did not receive the treatment.

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

View profiles in store

Company Profile – free sample

Your download email will arrive shortly

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Tick here to opt out of curated industry news, reports, and event updates from Pharmaceutical Technology.

Submit and download

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Initiating fosdenopterin treatment early, before the onset of significant brain damage, has been linked to preserved oral feeding abilities and enhanced growth, motor and cognitive development.

Pain, redness, discharge and inflammation were the most common side effects of the medicine linked to the catheter.

MHRA healthcare quality and access interim executive director Julian Beach stated: “Keeping patients safe and enabling their access to high quality, safe and effective medical products are key priorities for us.

“We’re assured that the appropriate regulatory standards for the approval of this medicine have been met. 

“As with all products, we will keep its safety under close review.”